 By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Licenses SARS-CoV-2 Vaccine On July 27, 2020, MediciNova, Inc. NASDAQ:MNOV announced the company entered into a joint development agreement with BioComo and Mie University for a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus HPIV type 2 vector. BioComo has initiated development of multiple vaccine 